| Drug Name | Sarilumab |
|---|---|
| Phase | Pre-Registration. |
| Indication | Adults with active moderate to severe rheumatoid arthritis and incomplete response to methotrexate. |
| Pharmacology description | Fully human monoclonal IgG1 antibody that binds specifically to the interleukin-6 receptor alpha |
| Route of Administration | Subcutaneous injection 150 or 200 mg every 2 weeks |
| Pivotal Trials | MOBILITY39, 45 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.